Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Technological platforms boost European cardiovascular research

13.12.2006
Proteomics, bioinformatics and Zebrafish are the novel tools set up by the European Vascular Genomics Network (EVGN).

Advanced technology is crucial to today’s biomedical research. But it is expensive and it requires specific expertise, which is expensive too. Then sharing becomes a must. And it guarantees a high level of cooperation among research groups throughout Europe. In 2006, the European Vascular Genomics Network (EVGN), a Network of Excellence funded by the European Union within its 6th Framework Programme, has launched three platforms, all of them representing cutting edge tools in the field of cardiovascular science and aimed at strengthening and improving the research effectiveness of the Network. The platforms were presented during the Third EVGN annual Conference (Toulouse, 11-14 December 2006).

The Zebrafish platform (Zebrafish, the fish Danio rerio, is an extremely versatile model organism in modern molecular biology) intends to provide EVGN scientists with a direct access to the Zebrafish model system for in vivo studies of cardiovascular development and disease. The Zebrafish platform is based at IFOM, the FIRC Institute of Molecular Oncology (Milan, Italy) and it is led by EVGN scientist Marina Mione.

The bioinformatics platform will provide EVGN researchers with a comprehensive set of software and web tools for storing, accessing, analyzing and elaborating the huge amount of data that comes from today’s high throughput technologies (in particular, gene and protein expression data). The platform is managed by Anton Horrevoets of the Academisch Medisch Centrum (University of Amsterdam).

Last but not least, an innovative proteomic platform has been launched, to perform advanced studies on structure and function of the proteins involved in the process of formation and development of cardiovascular disease. The promise of proteomics in this field is to carry out large scale-studies of gene expression at the protein level, providing the basis for a detailed understanding of pathophysiological mechanisms and leading to the discovery of potential targets for drug development. The EVGN proteomic platform is managed by Manuel Mayr, of the St George's Hospital Medical School (London, UK).

“EVGN platforms – explains EVGN scientific coordinator Alain Tedgui, of Inserm, Paris – represent essential tools to our network. These technologies are necessary for today’s research, but they are extremely expensive, and would not be affordable for individual institutes. Also, every platform requires specific and advanced expertise, and this is expensive too. Sharing human and technological resources becomes then crucial. Also, having common platforms guarantees that we all work with experts with both highly specific expertise and a solid background in cardiovascular disease.” More than being just core facilities, the EVGN platforms base their work on collaborative projects. “The scientists who work at the platforms – adds Tedgui – are not technicians, they are indeed involved in collaborative projects with several EVGN partners.”

The future of EVGN

EVGN, which was launched in 2004, will be active until the end of 2008. But its legacy will be taken on by new specific projects to be activated during the 7th Framework Programme. “What we have done here, with EVGN, was to lay the foundations of European vascular disease with a highly collaborative approach. Now we need to go on. Some of the area that will be covered by the new Programme – says Tedgui – will directly interest EVGN members. For example inflammatory and vascular remodelling, or stem cells in ischemic disease. Several groups and leaders of EVGN will join together and propose innovative actions in these fields of research.”

The European Vascular Genomics Network (EVGN) is the first Network of excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHM-CT-2003-503254).

The Third EVGN Annual Conference is supported by an unrestricted educational grant from Laboratoires SERVIER.

Francesca Noceti | alfa
Further information:
http://www.ifom-ieo-campus.it
http://www.evgn.org

Further reports about: Cardiovascular EVGN expensive vascular disease

More articles from Life Sciences:

nachricht Fine organic particles in the atmosphere are more often solid glass beads than liquid oil droplets
21.04.2017 | Max-Planck-Institut für Chemie

nachricht Study overturns seminal research about the developing nervous system
21.04.2017 | University of California - Los Angeles Health Sciences

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

Light rays from a supernova bent by the curvature of space-time around a galaxy

21.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>